Happy to share my last paper in JCO PO: Real-World Validation of #PurIST Classifier for Informing Therapy Selection in #PDAC ascopubs.org/doi/full/10.... Only Classical pts benefit from 1L FOLFIRINOX v. GemPac (33% relative risk reduction in death). Basal pts don't. #PancreaticCancer #Oncology
Steph
@stephw.bsky.social
🥯 🗽 🇺🇸 🇧🇪 PhD | Bioinformatics, Computational Biology, Genomics, Cancer
This morning I walked from 2nd Avenue to 11th Avenue along 60th street, looking for local news crews. Predictably there were a few that were sticking mics in car windows. I asked, “Hey, want to talk to a pedestrian as well?”
A new study this week showed how the most common blood test performed-—the CBC, complete blood count—contains a treasure chest of information that we are missing in reporting out to patients and doctors. erictopol.substack.com/p/your-lab-t...
It’s disappointing NYC isn’t leading the way on something so basic and so obviously right for a city that’s so pedestrian-focused.
French law requires “daylighting” all intersections—eliminating street parking within 5 m of crosswalks to improve pedestrian safety—by 2026. Paris will complete all intersections by end of 2025. SF will begin enforcing a similar law with fines beginning on Jan 1 www.sfmta.com/blog/statewi...